No price history available.
Key financial summary
Financials in CNY| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | CNYm | 1,559 | 2,348 | 3,150 | 1,958 | 2,309 | 2,777 | N/A | N/A |
| Operating profit | CNYm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net profit | CNYm | 175 | 241 | 315 | 20 | -11 | 193 | N/A | N/A |
| EPS reported | CNY | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating cashflow per share | CNY | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Capex per share | CNY | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF per share | CNY | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Free cash flow | CNYm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt | CNYm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value equity | CNYm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value per share | CNY | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Number of shares | m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| DPS (TTM paid) | CNY | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Financial summary
Financials in CNY| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/B LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/S LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/FCF LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/EBITDA LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/Sales LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Earnings Yield LTM | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Quality | |||||||||
| ROE | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| ROIC | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Sales | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Growth and momentum | |||||||||
| EPS Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Sales Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Income Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating Profit Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend and capital structure | |||||||||
| Dividend Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Payout Ratio | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Debt | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Debt/EBITDA | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EBIT/Net interest | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/market cap | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/Equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross debt/equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
Company overview
Suli Co., Ltd., based in Jiangyin, China, operates as a chemical manufacturer engaged in the research, production, and sale of a diverse range of fine chemicals. Their product portfolio encompasses agrochemicals, flame retardants, and pharmaceutical intermediates. Within agrochemicals, the company provides technical-grade active ingredients like chlorothalonil, azoxystrobin, diflubenzuron, fluazinam, cymoxanil, and boscalid, along with various prepared pesticide formulations. For flame retardants, Suli produces decabromodiphenyl ethane, in addition to offering brominated, environmentally friendly, and halogen-free options. Their extensive list of chemical intermediates includes compounds such as trichloroacetonitrile, tetrachlorophthalonitrile, pentachloropyridine, pentachlorobenzonitrile, isophthalodinitrile, hydrobromic acid, 1,2-diphenylethane, and 1,2-dibromoethane. Furthermore, the company manufactures industrial biocides under the "Longee" brand, featuring products like 985CHL, 550CCD, 550CC, and 500CHL. They also supply a ferric chloride solution, primarily utilized for water treatment. These products, sold under the "Suli" brand, cater to a variety of industries, including agricultural production, plastics manufacturing, and building materials. Suli Co., Ltd. maintains a significant global presence, distributing its goods across the European Union, North America, South America, Africa, Southeast Asia, and other international markets.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Based on consensus from external analysts. Not Kvantra's opinion.
Suli Co., Ltd., based in Jiangyin, China, operates as a chemical manufacturer engaged in the research, production, and sale of a diverse range of fine chemicals. Their product portfolio encompasses agrochemicals, flame retardants, and pharmaceutical intermediates. Within agrochemicals, the company provides technical-grade active ingredients like chlorothalonil, azoxystrobin, diflubenzuron, fluazinam, cymoxanil, and boscalid, along with various prepared pesticide formulations. For flame retardants, Suli produces decabromodiphenyl ethane, in addition to offering brominated, environmentally friendly, and halogen-free options. Their extensive list of chemical intermediates includes compounds such as trichloroacetonitrile, tetrachlorophthalonitrile, pentachloropyridine, pentachlorobenzonitrile, isophthalodinitrile, hydrobromic acid, 1,2-diphenylethane, and 1,2-dibromoethane. Furthermore, the company manufactures industrial biocides under the "Longee" brand, featuring products like 985CHL, 550CCD, 550CC, and 500CHL. They also supply a ferric chloride solution, primarily utilized for water treatment. These products, sold under the "Suli" brand, cater to a variety of industries, including agricultural production, plastics manufacturing, and building materials. Suli Co., Ltd. maintains a significant global presence, distributing its goods across the European Union, North America, South America, Africa, Southeast Asia, and other international markets.
